CJC-1295 with DAC vs ipamorelin compared: half-life, GH release pattern, dosing frequency, side effects, and why researchers study them differently.
CJC-1295 with DAC and ipamorelin are both research peptides that increase growth hormone release, but they act on different receptors and on completely different timelines. CJC-1295 with DAC is a long-acting GHRH analog that keeps GH and IGF-1 elevated for days, while ipamorelin is a short-acting ghrelin receptor agonist that produces brief, pulse-like GH release. The biggest practical difference between them is duration of action, and that single difference drives almost every other comparison.
Neither peptide is FDA-approved for human use in the United States. Both are sold as research chemicals only, and everything below describes what appears in the scientific literature and research settings, not a treatment recommendation.
What Is CJC-1295 With DAC?
CJC-1295 with DAC is a modified growth hormone-releasing hormone (GHRH) analog. The "DAC" stands for Drug Affinity Complex, a small molecular addition that binds the peptide to albumin in the bloodstream.
That albumin binding is what makes the molecule unusual. Instead of clearing in minutes, CJC-1295 with DAC has a reported half-life of roughly six to eight days, so a single injection can keep GH and IGF-1 levels elevated for a week or longer.
Because of that long half-life, many researchers prefer the shorter version of the same peptide backbone. Searches for buy cjc-1295 no dac usually refer to mod GRF 1-29, which is the identical sequence without the albumin-binding tag and clears in about 30 minutes rather than a week.
What Is Ipamorelin?
If you are asking what is ipamorelin peptide, the shortest answer is that it is a five-amino-acid peptide that activates the ghrelin receptor, also called the growth hormone secretagogue receptor. That is a different target than the one CJC-1295 uses.
Ipamorelin is known in the literature for being selective. Early animal studies found it triggered GH release without meaningfully raising cortisol, prolactin, or aldosterone, which is not true of older ghrelin agonists such as GHRP-6.
Its half-life is roughly two hours, so it produces a short GH pulse instead of a sustained elevation. That pulse pattern is closer to how the body releases growth hormone naturally during deep sleep and after intense exercise.
Head-to-Head Comparison
| Feature | CJC-1295 with DAC | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor | Ghrelin / GHS-R1a receptor |
| Reported half-life | About 6–8 days | About 2 hours |
| GH release pattern | Sustained, near-continuous | Pulsatile, short bursts |
| IGF-1 effect | Larger and longer-lasting | Smaller and shorter |
| Dosing frequency in research | Once weekly or every few days | One to three times daily |
| Appetite effect | Mild increase reported | Minimal compared with other ghrelin agonists |
| Most reported side effects | Injection site reactions, flushing, water retention, headache | Headache, flushing, transient hunger |
| US regulatory status | Not FDA-approved; research use only | Not FDA-approved; research use only |
The table highlights the core trade-off. CJC-1295 with DAC produces a bigger, longer signal, and ipamorelin produces a smaller, more physiological one.
A bigger signal is not automatically better. Sustained GH elevation can flatten the natural pulsatile rhythm the body relies on, which is why many researchers deliberately choose short-acting compounds for rhythm-focused work.
Dosing and Cycle Length in Research
Dosing schedules for these peptides come largely from small studies and community practice rather than large controlled human trials. No approved human dose exists for either compound.
In the published CJC-1295 with DAC study in HIV-associated lipodystrophy, participants received weekly subcutaneous injections in the microgram-per-kilogram range. Questions about cjc 1295 dac cycle length usually trace back to that weekly schedule, and community discussions typically describe blocks of about 8 to 12 weeks followed by a break.
Ipamorelin is described in much smaller individual amounts given once to three times per day, often timed around sleep or after training to mimic a natural pulse.
| Peptide | Reported research range | Frequency | Notes |
|---|---|---|---|
| CJC-1295 with DAC | Microgram-per-kilogram range in the published trial | Weekly | Sustained IGF-1 elevation; long washout period |
| Ipamorelin | Roughly 100–300 mcg per administration in community reports | 1–3 times daily | Short pulse; preserves pulsatility better |
These figures are descriptive, not prescriptive. Self-dosing with unapproved peptides carries real risk, including dosing errors and contamination from unregulated suppliers.
Stacking CJC-1295 With Ipamorelin
Many research discussions pair a GHRH analog with a ghrelin agonist because the two act on separate receptors and can amplify the same pulse. CJC-1295 without DAC and ipamorelin are the most commonly discussed combination, mainly because their timelines match.
CJC-1295 with DAC is a less common partner for ipamorelin, since a compound that stays active for a week does not need to be timed against a two-hour pulse. Researchers who combine them are usually trading pulsatility for convenience.
Human data on either combination is thin. People reading about metabolic compounds may also run into comparisons like aod 9604 vs mots-c, which sit in a different category entirely and should not be treated as interchangeable with GH-releasing peptides.
Safety, Side Effects, and Legal Status
Reported side effects for both peptides include injection site reactions, flushing, headache, and fluid retention. Sustained GH and IGF-1 elevation carries additional theoretical concerns, including blood sugar changes, joint swelling, and long-term effects on tissue growth.
CJC-1295 with DAC is not FDA-approved for human use, and ipamorelin is not FDA-approved either. Both are banned by WADA for athletes, and in the US they may be sold for laboratory research but not as dietary supplements or drugs for human consumption.
People comparing these peptides to prescription growth hormone, for example by searching omnitrope vs somatropin, are looking at a regulated pharmaceutical category with documented dosing, monitoring, and adverse-event reporting. Research peptides have none of that infrastructure.
Anyone considering these compounds should speak with a licensed healthcare professional. Blood work, IGF-1 monitoring, and a clear understanding of legal status matter far more than which peptide looks stronger in a forum post.
Which One Fits Your Research Question?
- Choose CJC-1295 with DAC for duration. It is the model compound when a study needs sustained GH and IGF-1 elevation from a single administration.
- Choose ipamorelin for pulsatility. It suits research on natural GH rhythm and selective ghrelin receptor activation.
- Choose CJC-1295 without DAC when timing matters. The short-acting form pairs more naturally with frequent-pulse study designs.
- Consider neither if you need an approved therapy. No peptide in this class has cleared FDA review for human use.
CJC-1295 with DAC and ipamorelin are not direct competitors so much as different instruments. One is a long-acting amplifier and the other is a short, selective pulse generator, and the better choice depends entirely on what a study is trying to measure.
Frequently Asked Questions
Is CJC-1295 with DAC stronger than ipamorelin?
CJC-1295 with DAC produces a larger and longer-lasting rise in GH and IGF-1 because its half-life is roughly six to eight days, compared with about two hours for ipamorelin. Stronger is not the same as better, since sustained elevation can blunt the body's natural pulsatile GH rhythm while ipamorelin tends to preserve it. Neither peptide is FDA-approved for human use in the United States.
Can you combine CJC-1295 with DAC and ipamorelin?
They act on different receptors, so pairing a GHRH analog with a ghrelin agonist is a common topic in research discussions and may amplify the same pulse. Human data on the combination is minimal, and the side-effect profile of long-term combined use is not well characterized. Anyone considering it should consult a licensed healthcare professional.
How long does CJC-1295 with DAC stay in your system?
CJC-1295 with DAC has a reported half-life of about six to eight days, and its effect on IGF-1 can persist for a week or more after a single dose. Full washout may take several weeks, which is why it is usually described as a weekly compound. Ipamorelin, by contrast, clears within hours.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.